期刊文献+

奥施康定治疗中重度癌痛临床观察 被引量:10

Clinical observation of oxycontin in management of moderate and severe cancer pain
下载PDF
导出
摘要 目的:观察盐酸羟考酮控释片(奥施康定)治疗中重度癌痛的疗效及不良反应。方法:采用开放试验方法,对49例中重度癌痛患者进行治疗。奥施康定起始剂量10mg/12h,根据疼痛缓解程度调整剂量,评价镇痛效果、KPS评分及不良反应。结果:49例中重度癌痛患者,平均镇痛时间12.45h。总有效率89.80%,中度疼痛组有效率93.75%,重度疼痛组有效率87.88%。KPS评分:28例(57.14%)升高,19例(38.78%)稳定,2例(4.08%)病情恶化死亡。不良反应主要为便秘7例(14.29%)。结论:奥施康定治疗中重度癌痛疗效确切,不良反应轻,服用安全。 Objective: To observe analgesic effect and main side effects of oxycontin in management of the moderate and severe cancer pain. Methods:Foyrtynine patients with moderate and severe cancer pain were selected. Oxyeontin was administered at an initial dose of 10mg every 12h and titrated upwards according to the extent of pain relief. Outcomes included analgesic effect, Karnofsky Performance Status Scales ( KPS ) and side effect. Results : Among all the 49 patients the mean duration of analgesic effect was 12.45h, total effective rate was 89.80% , effective rate of the moderate and severe cancer pain was 93.75% and 87.88% , respectively. KPS was elevated in 28 patients ( 57.14% ) and stable in 19(38.78% ) after application of oxycontin,2 patients(4.08% ) died. Main adverse effect was constipation in 7 patients( 14.29% ). Conclusion:Oxyeontin is safe and effective and with slight adverse effects in treatment of moderate and sever cancer pain.
出处 《现代肿瘤医学》 CAS 2009年第7期1335-1337,共3页 Journal of Modern Oncology
关键词 奥施康定 癌痛 疗效 不良反应 oxycontin cancer pain curative effect adverse effect
  • 相关文献

参考文献6

  • 1李春燕,孙呈祥.奥施康定片镇痛效果的临床观察[J].现代肿瘤医学,2006,14(5):611-612. 被引量:18
  • 2Reid CM, Martin RM, Sterne JA, et al. Oxycodone for cancer - related pain : meta - analysis of randomized controlled trials[ J]. Arch Intern Med,2006,166 ( 8 ) :837 - 843.
  • 3Biancofiore G. Oxycodone controlled release in cancer pain management[J]. Ther Clin Risk Manag,2006,2 ( 3 ) :229 - 234.
  • 4张广华,李锦成.奥施康定用于慢性癌性中重度疼痛的疗效观察[J].中国肿瘤临床,2008,35(13):733-735. 被引量:37
  • 5Jamison RN, Raymond SA, Slawsby EA. Opioid therapy for chronic noncancer back pain : A randomized prospective study [ J ]. Spine, 1998,23(23) :2591 -2600.
  • 6Ackerman SJ, Mordin M, Reblando J, et al. Patient reported utilization patterns of fentanyl transdermal system and oxyeodone hydrochloride controlled - release among patients with chronic nonmalignant pain[J]. J Manag Care Pharm,2003,9(3) :223 -231.

二级参考文献10

  • 1刘华,王蔚,郑垂志,邢雪花.癌症三阶梯止痛563例分析[J].中国肿瘤临床,2004,31(23):1346-1348. 被引量:79
  • 2刘振华,李卉,李彦,丁全福.盐酸羟考酮控释治疗中、重度疼痛研究进展[J].武警医学,2005,16(3):211-213. 被引量:20
  • 3徐国柱,蔡志基.镇痛药临床评价方法研究[J].中国新药杂志,1995,4(4):20-22. 被引量:256
  • 4张冠中,谢晓冬,刘大为.盐酸羟考酮控释片治疗晚期癌症疼痛的临床应用[J].中国肿瘤临床,2007,34(2):72-74. 被引量:25
  • 5狄伟文 程高升 游在英.芬太尼—利多卡因合剂用于手术后切口敷料镇痛临床观察[J].临床麻醉学杂志,2000,16(2):69-69.
  • 6Clohisy DR, Mantyh PW. Bone cancer pain[J]. Cancer,2003, 97 (3 Suppl): 866-873.
  • 7Jamison RN, Raymond SA, Slawsby EA. Opioid therapy for chronic noncancer back pain. A randomized prospective smdy[J]. Spnie, 1998, 23(23): 2591-2600.
  • 8Mandema JW, Kaiko RF, Oshlack B, et al. Characterization and validation of a pharmacokinedc model for controlled-release oxycodone[J]. Br J Clin Pharmacol, 1996, 42(6): 747-756.
  • 9Watson CP, Moulin D, WattWatson J, et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy[J]. Pain, 2003, 105(1-2): 71-78.
  • 10Ackerman SJ, Mordin M, Reblando J, et al. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochlorlde controlled-release among patients with chronic nonmalignant pain[J].J Manag Care Pharm, 2003, 9(3): 223-231.

共引文献52

同被引文献96

引证文献10

二级引证文献117

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部